{"nctId":"NCT00801723","briefTitle":"(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.","startDateStruct":{"date":"2008-12"},"conditions":["Ulcerative Colitis"],"count":123,"armGroups":[{"label":"1: Budesonide MMX® 6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide MMX 6 mg Tablet"]},{"label":"2: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Tablet"]}],"interventions":[{"name":"Budesonide MMX 6 mg Tablet","otherNames":[]},{"name":"Placebo Tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients fulfilling the following criteria are eligible for participation in the study:\n\n  * Male and female patients, 18-75 years old, who are able to understand and voluntarily provide written informed consent.\n  * Patients in UCDAI remission defined as a UCDAI score ≤ 1 point with a score of 0 for rectal bleeding and stool frequency, and a ≥ 1 point reduction from baseline in the endoscopy score without any sign of mucosal friability (score 0 for mucosal appearance).\n  * Patients who have completed all End of Study assessments for the CB-01-02/01, CB-01-02/02 and CB-01-02/06 studies.\n  * Females of child-bearing potential must have had a serum pregnancy test performed at the End of Study visit of the parent studies and must use an acceptable contraceptive method throughout the study treatment period.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria at screening visit are to be excluded from study participation:\n\n  * Subjects who have withdrawn from studies CB-01-02/01, CB 01 02/02 or CB-01-02/06.\n  * Subjects who did not achieve induction of remission according to the primary endpoint definition in studies CB-01-02/01, CB 01 02/02 or CB-01-02/06 (i.e. clinical remission defined as a UCDAI score ≤ 1 point with a score of 0 for rectal bleeding and stool frequency, and ≥ 1 point reduction from baseline in the endoscopy score without any sign of mucosal friability \\[score 0 for mucosal appearance\\]).\n  * Subjects with bone density lower than normal by age and sex (T-score lower than -1) as assessed via dual energy X-ray absorptiometry (DXA) scans.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Clinical Remission","description":"Clinical remission was defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Relapse","description":"Clinical relapse was defined as the recurrence of rectal bleeding and/or an abnormal stool frequency \\[≥ 1-2 stools/day above normal for the participant. Clinical remission/relapse status was based on participant diary entries prior to each scheduled visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Endoscopic Relapse","description":"Endoscopic relapse was defined as an increase of ≥ 2 points in the Endoscopic Index score from the value calculated at baseline. The score is comprised of four components (granulated scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage). Scores range from 0 to 12, and higher scores indicate more severe (worse) endoscopic findings.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":61},"commonTop":["Colitis ulcerative","Abdominal pain","Headache","Osteopenia","Frequent bowel movements"]}}}